MARKET

ACRX

ACRX

Acelrx Pharma
NASDAQ
0.8300
+0.0660
+8.64%
After Hours: 0.8001 -0.0299 -3.60% 19:30 12/04 EST
OPEN
0.7615
PREV CLOSE
0.7640
HIGH
0.8400
LOW
0.7500
VOLUME
79.88K
TURNOVER
0
52 WEEK HIGH
2.780
52 WEEK LOW
0.4250
MARKET CAP
14.07M
P/E (TTM)
-0.2859
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ACRX last week (1127-1201)?
Weekly Report · 1d ago
Acelrx Pharma: Notice of Effectiveness
Press release · 4d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Adial pharmaceuticals shares increased by 30.5% to $2.78 during wednesday's after-market session. Dyadic international (nasdaq:dyai) shares rose by 9.35%. Acelrx pharmaceuticals, neximmune and revelation biosciences also gained.
Benzinga · 5d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Senestech stock rose 42.0% to $2.67 during monday's after-market session. Tc biopharm (holdings) shares rose 17.71%. Heart test laboratories (nasdaq:hscs) stock rose 15.99% and uphealth shares rose 10.66%. Losers include centessa pharmaceuticals and onemednet.
Benzinga · 11/27 21:31
Weekly Report: what happened at ACRX last week (1120-1124)?
Weekly Report · 11/27 12:21
Acelrx Pharma: Securities to be offered to employees in employee benefit plans
Press release · 11/23 00:06
Acelrx Pharma: Registration statement under Securities Act of 1933
Press release · 11/23 00:06
AcelRx Pharmaceuticals files for $150M mixed shelf
Healthcare acelrx pharmaceuticals files for $150m mixed shelf nov. 22, 2023. The company filed a prospectus for a mixed securities shelf offering of up to $150 million. Acelrx is a subsidiary of acel pharmaceuticals, inc.
Seeking Alpha · 11/22 21:45
More
About ACRX
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is its nafamostat formulation for direct intravenous (IV) infusion being explored as an investigational product for the antiviral treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. Its pre-filled syringe product candidates include Fedsyra and Phenylephrine.

Webull offers AcelRx Pharmaceuticals Inc stock information, including NASDAQ: ACRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACRX stock methods without spending real money on the virtual paper trading platform.